Complement control for COVID-19

Excessive complement activation contributes to lung disease and adverse patient outcomes in COVID-19 (see the related research articles by Yan et al. and Ma et al.).

Detalles Bibliográficos
Autor principal: Bosmann, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2021
Materias:
Focus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432947/
https://www.ncbi.nlm.nih.gov/pubmed/34035117
http://dx.doi.org/10.1126/sciimmunol.abj1014
Descripción
Sumario:Excessive complement activation contributes to lung disease and adverse patient outcomes in COVID-19 (see the related research articles by Yan et al. and Ma et al.).

Ejemplares similares